Bioyitech showcased its presence at SupplySide Global 2025, highlighting its leading clinical strains that are setting new trends in health and wellness.
The 2025 Western United States International Health Industry Expo (hereinafter referred to as the "Western U.S. Expo"), the world's most influential health technology event, recently concluded successfully in Las Vegas. Bioyitech (Shanghai) Biotechnology Co., Ltd. made a stunning appearance, showcasing two major scientific research achievements – functional bacterial strains with clinical evidence from top-tier hospitals. This presentation highlighted China's innovative strength in the field of microecological health on the international stage, becoming a focal point of significant attention during the exhibition.
Innovative achievements shine on the international stage.
As the industry's most influential annual event, the Western States Exposition showcased the latest technological achievements and cutting-edge trends in the global health industry. Bioyitech's two core strain technologies, with their clear clinical positioning and solid research data, attracted significant interest from numerous international peers, potential partners, and professional attendees.
New Breakthroughs in Gout Prevention and Uric Acid Management:
JiangXiaoYi Uric Acid Lowering Series –Clinical Registration Number ChiCTR2500096029
As the global prevalence of gout continues to rise, uric acid management has become a critical issue in international health. Bioyitech introduces the JiangXiaoYi Uric Acid Lowering Series of Probiotics, supported by clinical evidence from top-tier hospitals. With its unique uric acid-lowering mechanisms, this series offers a novel solution for gout prevention and management.
Validated through rigorous clinical trials, this series demonstrates significant efficacy in reducing uric acid levels, thereby mitigating the risk of gout attacks at its source. Compared to traditional pharmacological therapies, this microbial intervention approach is more natural and gentle, providing a sustainable new option for long-term uric acid management.
Innovative Solutions for Dual Regulation of Blood Glucose and Lipids:
JiangXiaoYi Glucose Lowering Series – Clinical Registration Number ChiCTR2400089551
In response to the escalating incidence of diabetes and dyslipidemia worldwide, Bioyitech's JiangXiaoYi Glucose Lowering Series, also backed by clinical evidence from leading hospitals, has garnered significant attention. This composite probiotic formulation modulates the intestinal microecological balance to achieve bidirectional regulation of blood glucose and lipids, offering an innovative strategy for the prevention and control of metabolic syndrome.
Clinical studies indicate that this composite probiotic not only effectively enhances insulin sensitivity, aiding in stable glucose maintenance, but also promotes lipid metabolism balance, providing multi-faceted protection for cardiovascular and cerebrovascular health. This comprehensive intervention strategy, rooted in gut microbiota modulation, represents a new direction in the field of chronic disease management.
International Exchange, Joint Exploration of the Future of Microbiome Health
Throughout the exhibition, Bioyitech's booth was consistently bustling with visitors. Industry experts and corporate representatives from North America, Europe, Asia, and other regions expressed strong interest in potential collaborations regarding our two innovative synbiotic products. Our technical team engaged in in-depth discussions with international peers, covering topics such as strain mechanisms of action, clinical application prospects, and industrialization feasibility.
"We are delighted to witness the international market's recognition of original Chinese microbiome technology," stated Li Jiadong, CEO of Bioyitech. "This exhibition has not only showcased our research achievements but, more importantly, has established invaluable communication channels with global counterparts, laying a solid foundation for future international partnerships."